Chasing Cures. Delivering Hope™
Delivering the future of gene therapy
WELCOME TO AVIADOBIO
At AviadoBio, we are relentlessly chasing cures by developing and translating groundbreaking science and precision delivery into life-changing medicines across neurodegenerative diseases.
With our deep understanding of the brain and our suite of proprietary gene therapy platforms and delivery technologies, we are working relentlessly to overcome the challenges of delivering the right drug to the right place. Our innovative, neuroanatomy-led approach is designed to maximize the therapeutic potential of gene therapy to potentially delay or even halt the progress of neurodegenerative disease.
pioneering research
Our focus is to maximise biodistribution to the neuronal tissue across the brain and eye through targeted gene therapy and precision delivery. We believe delivery to be the game changer in overcoming challenges with existing treatment pathways.
AviadoBio was formed based on pioneering research from King’s College London and the UK Dementia Research Institute.
OUR MISSION
Hear directly from our CEO, Lisa Deschamps, about our commitment to translate groundbreaking science and precision delivery into potentially life-changing medicines.
AN UNMET MEDICAL NEED
Neurodegenerative diseases are depriving people of the prime years of their lives and have a devastating impact on families and loved ones. Few to no treatments exist for many of these diseases despite many decades of research.
Recent progress and successes in genetic medicine have demonstrated its great promise in treating previously untreatable, life-threatening neurological diseases
AviadoBio’s pipeline spans frontotemporal dementia (FTD), retinal dystrophies like retinitis pigmentosa and geographic atrophies, amyotrophic lateral sclerosis (ALS), and tauopathies, including Alzheimer’s disease. The company seeks to treat complex neural systems across the brain, spinal cord and retina using optimized gene therapy constructs, capsids and administration routes, to overcome the delivery and safety challenges of treating neurological disorders.
Its proprietary, best-in-class vMiX™ platform is designed for one-time RNA silencing of gain-of-function gene targets and disease pathways.
Starting from a promise…
“Our motivation is to fulfill a promise given to a generation of patients for whom there were no effective treatments but who shared their experiences and bodies so that we could find cures to treat their children.”
Prof. Chris Shaw
Chief Scientific and Clinical Advisor/Co-Founder
Prof. Chris Shaw
Chief Scientific and Clinical Advisor/Co-Founder
About Us
Join Us
Our Science
A Phase 1/2 open-label clinical study to evaluate the safety and preliminary efficacy of AVB-101 in people with a genetic sub-type of frontotemporal dementia (FTD-GRN) is now open for enrollment.
